Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ADXS $9.89 1.6600 +20.17%
ZIOP $8.93 0.9300 +11.63%
RDUS $44.29 3.3500 +8.18%
PVCT $0.85 0.0600 +7.59%
CVM $0.72 0.0500 +7.46%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $16.14 -0.7900 -4.67%
VICL $1.03 -0.0500 -4.63%
CRIS $1.87 -0.0700 -3.61%
VSTM $7.45 -0.2700 -3.50%
KERX $13.07 -0.3800 -2.83%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

FDA Approves Roche Ebola Test for Emergency Use

(Reuters) Dec 29, 2014 - Roche Holding AG said U.S. health regulators have approved its Ebola test for emergency use in response to the world's worst outbreak of the disease in West Africa.
read article 

FDA Approves Weight-management Drug Saxenda

( Dec 23, 2014 - The U.S. Food and Drug Administration today approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
read press release 

Pharma and Biotech on a Roll as Drug Approvals Hit 18-year High

(Reuters) Jan 1, 2015 - U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases.
read article 

Multiple Pay Cuts Hit Doctors In 2015

(Forbes) Jan 1, 2015 - A flurry of pay cuts for doctors hit today as physicians struggle to implement electronic health records, deal with new measurements to improve quality and deal with myriad changes in Medicare and Medicaid reimbursement formulas.
read article 

Dendreon Heads to Auction Without Initial Bidder

(Reuters) Dec 29, 2014 - Bankrupt cancer vaccine maker Dendreon Corp will move ahead with a court-supervised auction of the company without a customary initial bidder, known as a stalking horse, the company's attorney said on Monday.
read article 

Top Cancer Society Exec Quits

(MedPage Today) Dec 23, 2014 - Architect of ACS "transformation" may have transformed himself out of a job.
read article (free registration required) 

CMS to Hold 2015 Date-of-Service Claims for Services Paid Under the MPFS for Two Weeks

(ACCC) Jan 5, 2015 - In order to implement corrections to technical errors discovered after publication of the 2015 Medicare Physician Fee Schedule (MPFS) rule and process claims correctly, Medicare Administrative Contractors will hold claims containing 2015 services paid under the MPFS for the first 14 calendar days of January 2015.
read article 

ASCO Expresses Concern About OHRP Draft Guidance on Research Risk Disclosure

(ASCO in Action) Dec 23, 2014 - ASCO has submitted comments to the U.S. Office for Human Research Protections regarding a draft guidance, “Disclosing Reasonably Foreseeable Risks in Research Evaluating Standards of Care.”
read article 

ASCO Objects to ABLE Act’s Non-Medicare Use of Medicare Offsets

(ASCO in Action) Dec 23, 2014 - Congress has passed, and the President has signed, the “Achieving a Better Life Experience (ABLE) Act,” which will allow individuals with disabilities to create tax-free savings accounts, while protecting their access to Medicaid.
read article 

Cancer Genetics, Inc. Receives Approval to Provide Oncology Testing for Patients in California

(Cancer Genetics) Jan 5, 2015 - Cancer Genetics, Inc. announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.
read corporate press release 

Exact Sciences: Additional Update on CMS Reimbursement for Cologuard®

(MarketWatch) Jan 2, 2015 - Exact Sciences Corp. today announced that the Centers for Medicare and Medicaid Services (CMS) has published an updated 2015 Clinical Laboratory Fee Schedule, which includes reimbursement for Exact Sciences’ Cologuard® noninvasive colon cancer screening test (CPT code G0464) at $492.72.
read article 

Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

( Dec 27, 2014 - Approval is being sought for use as a high-dose conditioning treatment prior to stem cell transplantation in multiple myeloma and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate; the Company expects FDA review to take approximately 10 months.
read article 

Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia

(Morningstar) Dec 30, 2014 - Idera Pharmaceuticals, Inc. today announced that the FDA has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of Waldenström's macroglobulinemia (WM). Additionally, Idera is providing a progress update on the ongoing Phase 1/2 clinical trial being conducted in WM.
read article 

Otsuka Joins Ariad in $77.5M+ Deal to Commercialize Iclusig in Asia

(Genetic Engineering & Biotechnology News) Dec 23, 2014 - Otsuka Pharmaceutical will commercialize Ariad Pharmaceuticals’ leukemia treatment Iclusig® (ponatinib) in Japan and nine other Asian countries, as well as fund future clinical trials in those countries. The deal could net Ariad as much as $77.5 million-plus, the companies said today.
read article (free registration required) 

OncoGenex Regains Rights to Prostate and Lung Cancer Drug

(Drug Discovery & Development) Dec 30, 2014 - OncoGenex Pharmaceuticals Inc. announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
read article (free registration required) 

Amgen and Kite Pharma in Cancer Immunotherapy Pact

(Wall Street Journal) Jan 5, 2015 - Amgen and Kite Pharma reached a research collaboration and license agreement to develop cancer immunotherapy treatments.
read article (paid subscription required) 

Big Pharma Waits Decision on Cancer Drugs

(Financial Times) Jan 4, 2015 - Tensions are rising between pharmaceutical companies and the UK government, as the industry braces for a decision on which drugs will be axed from a special fund for expensive cancer therapies.
read article (free registration required) 

The Most Important New Drug Of 2014

(Forbes) Dec 30, 2014 - It’s a tie. Since 2012, I’ve been picking the most important new medicine approved each year. It’s always a tight competition, but this year the two obvious winners are so alike that I think it’s not fair to give either an edge.
read article 

Why Eating Red Meat Raises Cancer Risk

(San Diego Union-Tribune) Dec 29, 2014 - Red meat elevates the risk of cancer because it contains a chemical that’s unnatural to human biology, according to a new study by UC San Diego scientists.
read article 

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study

(MarketWatch) Dec 24, 2014 - Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.
read article 

Tool Helping UC Cancer Institute Identify Patients At-Risk for Malnutrition

(University of Cincinnati) Dec 29, 2014 - Dieticians at the UC Cancer Institute have rolled out a pilot study in select cancer clinics to determine if the use of a validated malnutrition screening tool given at the time of a cancer patient’s first visit will help in identifying those who are at risk.
read article 

Rare Cancer's Genetic Pathway Identified by Scientists

(Simon Fraser University [Burnaby, B.C., Canada]) Dec 23, 2014 - An international research team, including four Simon Fraser University scientists, has identified the "mutational landscape" of intrahepatic cholangiocarcinoma (ICC), a rare, highly fatal form of liver cancer that disproportionately affects people in Asian countries.
read press release 

Researchers Confirm Whole-genome Sequencing Can Successfully Identify Cancer-related Mutations

(UT Southwestern) Dec 23, 2014 - UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients’ risk for hereditary cancer, which can potentially lead to improvements in cancer prevention, diagnosis, and care.
read press release 

A Key Molecular Defect in a Childhood Gastrointestinal Tumor May Have Important Diagnostic Implications

(NCI News Note) Dec 24, 2014 - NCI scientists have identified a key molecular defect that may have important diagnostic implications in a tumor in children known as gastrointestinal stromal tumor, or GIST.
read article 

Self-exam and Doctor's-exam Find Similar Breast Tumors

(Reuters) Dec 25, 2014 - Women’s self-exams and physical exams by a doctor both detect breast cancer tumors at about the same size, but older women are more likely to have a tumor discovered via doctor’s examination, according to a new Swiss study.
read article